FDA Approves Rituximab Plus Hyaluronidase Combination for Treatment of FL, DLBCL and CLL
Jun 21
2017
The U.S. Food and Drug Administration granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA, Genentech Inc.) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
